Acid Phosphatase, Prostate (ACPP) Antikörper

Antigen: Acid Phosphatase, Prostate (ACPP)

Synonyme: PAP, ACP3, ACP-3, Lap, Ppal, AI324033, A030005E02Rik, pap, Acpp11, RNACPP11, ACPP, MGC159906, acpt, MGC130636

Klonalität: Monoklonal (PASE-4LJ)

Wirt: Maus

Reaktivität: Human

Applikation: Immunhistochemie (Paraffinschnitte) (IHC (p))

Zertifikate: ISO 9001:2008, ISO 13485:2003

Anbieter: Dako

Produktnummer: ABIN370598

Produktbeschreibung

Weitere Bezeichnung: Prostatic Acid Phosphatase

Immunogen: Purified prostatic acid phosphatase from human seminal plasma (1).

Isotyp: IgG1, kappa chain  (Passende Sekundärantikörper)

Klon: PASE-4LJ

Beschreibung: Synonyms for antigen PAP (1, 2), PSAP (3). Summary and explanation Prostatic acid phosphatase (PAP) belongs to the group of acid phosphatase isoenzymes (EC 3.1.3.2). It is found in large amounts in the prostate, and the concentration in seminal fluid is approximately 1 g/L (1, 2, 4). PAP is synthesized in the secretory epithelial cells in the normal prostate gland. The physiological function of PAP is not known. Chemically it hydrolyzes a wide variety of phosphomonoesters under acidic conditions and is inhibited by L-tartrate. These features make PAP belong to the group of tartrate-inhibitable acid phosphatases, which also includes lysosomal acid phosphatase (4). In highly differentiated tumours of prostatic origin, an abundance of cells are labelled by antibodies to PAP, whereas PAP-immunoreactive cells are less abundant in moderately (grade I) and poorly differentiated (grade II) carcinomas. The tumour cells of these grade I and II carcinomas also show a greater staining variability (4). Immunocytochemical data suggests that detection of PAP is a relatively sensitive and specific test for the prostatic origin of an otherwise unclassifiable primary or metastatic neoplasm (3).

Spezifität: In Western blotting of whole seminal plasma, the antibody labels a single band of 52 kDa corresponding to prostatic acid phophatase (1). In ELISA the antibody specifically reacts with human semen excluding all other bodily excretions, including vaginal fluid, blood, saliva, female urine, nasal discharge, earwax, sweat and faeces. Additionally semen from dog, goat, pig, ox and sheep are negative, whereas the antibody cross-reacts with semen from non-human primates, including vervet monkey and chacma baboon (5). As demonstrated by immunocytochemistry, the antibody shows no cross-reactivity with the prostatic acid phosphatase-equivalent protein in dog, rabbit, and rat (2).

Anwendungen

Applikationshinweise: Paraffin sections: The antibody can be used for labelling paraffin-embedded tissue sections fixed in formalin, formal acetic acid, Bouin's formal sublimate or methacarn. Additionally bone trephines decalcified in either EDTA or in formic/citric acid may be used (2). Pre-treatment of tissues with heat-induced epitope retrieval is recommended. For tissues fixed in formalin, optimal results are obtained with Dako Target Retrieval Solution, code S1700, Dako Target Retrieval Solution, High pH, code S3308, 10 mmol/L citrate buffer, pH 6.0, or 10 mmol/L Tris buffer, 1 mmol/L EDTA, pH 9.0. Pre-treatment of tissues with proteinase K was found destructive of the epitope. The tissue sections should not dry out during the treatment or during the following immunohistochemical staining procedure. . Frozen sections and cell preparations: The antibody can be used for labelling acetone-fixed, frozen sections (2, 6). Dilution: Monoclonal Mouse Anti-Human Prostatic Acid Phosphatase, code M0792, may be used at a dilution range of 1:200-1:400 when applied on formalin-fixed, paraffin-embedded sections of human prostate and using 20 minutes heat-induced epitope retrieval in Dako Target Retrieval Solution, code S1700, and 30 minutes incubation at room temperature with the primary antibody. Optimal conditions may vary depending on specimen and preparation method, and should be determined by each individual laboratory. The recommended negative control is Dako Mouse IgG1, code X0931, diluted to the same mouse IgG concentration as the primary antibody. Unless the stability of the diluted antibody and negative control has been established in the actual staining procedure, it is recommended to dilute these reagents immediately before use, or dilute in Dako Antibody Diluent, code S0809. Positive and negative controls should be run simultaneously with patient specimen. Visualization: Dako LSAB/HRP kit, code K0679, and Dako EnVision/HRP kits, codes K4004 and K4006, are recommended. For frozen sections and cell preparations, the Dako APAAP kit, code K0670, is a good alternative if endogenous peroxidase staining is a concern. Follow the procedure enclosed with the selected visualization kit. Performance characteristics: Cells labelled by the antibody display a cytoplasmic staining pattern.

Buffer: Monoclonal mouse antibody provided in liquid form as cell culture supernatant dialysed against 0.05 mol/L Tris/HCl, pH 7.2, and containing 15 mmol/L NaN 3 .

Lagerung: Store at 2-8 °C. Precautions: 1. For professional users. 2. This product contains sodium azide (NaN 3 ), a chemical highly toxic in pure form. At product concentrations, though not classified as hazardous, sodium azide may react with lead and copper plumbing to form highly explosive build-ups of metal azides. Upon disposal, flush with large volumes of water to prevent metal azide build-up in plumbing. 3. As with any product derived from biological sources, proper handling procedures should be used. 4. Wear appropriate Personal Protective Equipment to avoid contact with eyes and skin. 5. Unused solution should be disposed of according to local, State and Federal regulations.

Forschungsgebiet: Enzyme

Beschränkungen: Für Forschungszwecke. Als CE-zertifizierter Antikörper in der Europäischen Union für In Vitro Diagnostik (IVD) zugelassen.

Publikationen

Publikationen: Kang, Lemaire, Unterbeck et al.: "The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor." in: Nature, Vol. 325, Issue 6106, pp. 733-6, 1987 (PubMed).

Tanzi, McClatchey, Lamperti et al.: "Protease inhibitor domain encoded by an amyloid protein precursor mRNA associated with Alzheimer's disease." in: Nature, Vol. 331, Issue 6156, pp. 528-30, 1988 (PubMed).

Akiyama, Schwab, Kondo et al.: "Granules in glial cells of patients with Alzheimer's disease are immunopositive for C-terminal sequences of beta-amyloid protein." in: Neuroscience letters, Vol. 206, Issue 2-3, pp. 169-72, 1996 (PubMed).

Akiyama, Mori, Saido et al.: "Occurrence of the diffuse amyloid beta-protein (Abeta) deposits with numerous Abeta-containing glial cells in the cerebral cortex of patients with Alzheimer's disease." in: Glia, Vol. 25, Issue 4, pp. 324-31, 1999 (PubMed).

Bayer, Wirths, Majtuenyi et al.: "Key factors in Alzheimer's disease: beta-amyloid precursor protein processing, metabolism and intraneuronal transport." in: Brain pathology (Zurich, Switzerland), Vol. 11, Issue 1, pp. 1-11, 2000 (PubMed).

Papaioannou, Tooten, van Ederen et al.: "Immunohistochemical investigation of the brain of aged dogs. I. Detection of neurofibrillary tangles and of 4-hydroxynonenal protein, an oxidative damage product, in senile plaques." in: Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis, Vol. 8, Issue 1, pp. 11-21, 2001 (PubMed).

Matsunaga, Saito, Fujii et al.: "A pH-dependent conformational transition of Abeta peptide and physicochemical properties of the conformers in the glial cell." in: The Biochemical journal, Vol. 361, Issue Pt 3, pp. 547-56, 2002 (PubMed).

Morishima-Kawashima, Ihara: "Alzheimer's disease: beta-Amyloid protein and tau." in: Journal of neuroscience research, Vol. 70, Issue 3, pp. 392-401, 2002 (PubMed).